SCHEMBL26807176

SCHEMBL26807176

CC(=O)Nc1ccc(Oc2cc(-c3ccccc3C)nc(NS(=O)(=O)c3cccc(N)c3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G7 Q13093 2/20 0.46
▸ ACHE P22303 1/20 0.45
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ MAPT P10636 5/20 0.43
▸ PKM P14618 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26807167 0.90 MAPT (0.45) CA12CA1CA2CA9MAPT
SCHEMBL26823972 0.89 CA12 (0.41) PLA2G7CA12CA1CA2CA9
SCHEMBL24309603 0.89 POLB (0.45) CA12CA1CA2CA9MAPT
SCHEMBL26807174 0.89 CA12 (0.39) CA12CA1CA2CA9MAPT
SCHEMBL26807160 0.89 CA12 (0.41) CA12CA1CA2CA9MAPT
SCHEMBL29566945 0.88 PKM (0.49) PLA2G7MAPTPKMATMKDM4E
SCHEMBL24309588 0.88 PKM (0.49) PLA2G7MAPTPKMATMKDM4E
SCHEMBL24309292 0.88 TSHR (0.39) CA12CA1CA2CA9MAPT
SCHEMBL29567014 0.88 TSHR (0.39) CA12CA1CA2CA9MAPT
SCHEMBL24330515 0.84 ALDH1A1 (0.43) MEN1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B PLA2G7 741/4885ACHE 4826/4885CA12 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback